Daily Stock List
Carpathian Gold, Inc. (CPN.TO)
Today we are reporting on Carpathian Gold, Inc. (CPN.TO), here at the QualityStocks Daily Newsletter.
Carpathian Gold, Inc. is an exploration and development company that lists on the Toronto Stock Exchange. Their primary business interest is developing near-term gold production on their 100 percent owned Riacho dos Machados (RDM) Gold Project in Brazil, which is currently focusing on activities surrounding permitting and construction. Carpathian Gold has their headquarters in Toronto, Ontario.
The Company is also advancing their exploration and development plans on their 100 percent owned Rovina Valley Au-Cu Project (RVP) located in Romania. They believe the Rovina Valley Project will enhance Carpathian Gold's growth profile as a mid-tier gold producer.
Their RDM Gold Project is targeted to produce approximately +/-100,000 ounces of gold annually with an anticipated goal for the start of production in the second half of 2013.
Carpathian Gold (on a company wide basis) currently hosts NI 43-101 proven plus probable reserves of 830,200 ounces of gold (proven reserves of 2,300 Kt at 1.30 g/t Au and probable reserves of 18,500 Kt at 1.23 g/t Au). They also host NI 43-101 mineral resources (inclusive of reserves) of approximately 8.1 million ounces of gold in the measured plus indicated categories (RVP: 405.9 million tonnes at 0.55 g/t Au for 7.19 million ounces, RDM: 19.36 million tonnes at 1.50 g/t Au for 0.936 million ounces).
Moreover, they host approximately 0.9 million ounces of gold in the inferred category (RVP: 26.8 million tones at 0.38 g/t Au for 0.33 million ounces, RDM; 9.447 million tones at 1.93 g/t Au for 0.587 million ounces). In addition, they host 1.4 billion pounds of copper in the measured plus indicated category (RVP: 405.9 million tones at 0.16 percent Cu) and 97.0 million pounds of copper in the inferred category (RVP: 405.9 million tonnes at 0.16 percent Cu).
On October 1, 2012, Carpathian Gold provided an overview progress update on the development of the RDM Project as of that date. The Project remains on track with the overall construction and development time-line schedule for gold production in the second half of 2013. Approximately 45 percent of the Project was completed as of October 1, 2012. An optimized mine production plan was completed which shows approximately 100,000 ounces of gold production on an annual basis, scheduled to begin in the second half of 2013. The process plant start-up is still scheduled for June/July 2013.
Carpathian Gold, Inc. (CPN.TO), closed Monday's session at $0.31, up 5.08%, on 171,826 volume. The stock's 52-week low/high is $0.24/$0.60.
POW! Entertainment, Inc. (POWN)
Nebula Stocks and OTC Picks reported previously on POW! Entertainment, Inc. (POWN), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.
Listed on the OTCQB, POW! Entertainment, Inc. engages in the business of creating and licensing intellectual properties for the entertainment industry. The Company develops their properties in traditional entertainment media. These include feature length films in live action and animation, television programming, merchandising as well as related ancillary markets (i.e. merchandise, apparel, etc.). POW! Entertainment has their corporate headquarters in Beverly Hills, California.
World famous comic book icon Stan Lee together with Gill Champion and Arthur Lieberman founded POW! (Purveyors of Wonder) Entertainment. The Company is also focusing on content in media such as mobile applications, on-line, and video games. POW! Entertainment established in 2001; they became a public company in 2004 and a reporting company in December of 2010.
POW! Entertainment's assets consist of all intellectual properties owned and created by Stan Lee from 2001 onwards. Properties include ownership in perpetuity to Stan Lee's name, likeness, and brand and signature slogans: "Stan Lee Presents", "Excelsior", and "Stan's Soap Box". Stan Lee (Founder, Chairman, Board of Director, and Chief Creative Officer) is the creator of Spider-Man, Iron Man, Hulk, X-Men, and hundreds of other iconic comics.
He has also teamed up with Disney. POW! Entertainment previously signed an agreement with Silver Creek Pictures, Inc., for the term of five years ending in December 2014. Silver Creek Pictures is an affiliate of the Walt Disney Company. The agreement calls for POW! to provide Silver Creek Pictures with a "first look" at all of POW!'s creative intellectual property and the right to acquire any such properties at Silver Creek Picture's discretion.
POW! Entertainment's strategy takes advantage of the creative output of Stan Lee with minimal initial cash investment. They accomplish this through outsourcing creative talent for specific projects and working with larger production entities to complete the more labor and capital-intensive stages of project development, distribution, and marketing.
In mid-November, Moonshark, Inc. in partnership with Stan Lee's POW! Entertainment announced the launch of Verticus, Lee's first game for iPhone, iPad and iPod touch. It underwent development by Dallas, Texas-based Controlled Chaos Media. Moonshark's mission is to collaborate with the entertainment industry's most creative talent - like Stan Lee - to create cutting-edge, engaging and original mobile content and experiences.
POW! Entertainment, Inc. (POWN), closed Monday's trading session at $0.113, up 182.50%, on 2,388,289,900 volume with 385 trades. The average volume for the last 60 days is 21,426 and the stock's 52-week low/high is $0.03/$0.15.
Revolutionary Concepts, Inc. (REVO)
Lions of Wall Street reported this month on Revolutionary Concepts, Inc. (REVO), Greenbackers, Pennystocktweeters.com did earlier, and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.
Founded in 2004, Revolutionary Concepts, Inc. is a development stage company that focuses on the design and development of the Eye Talk Communicator - a smart camera technology. It serves as an entry management system. It gives users the ability to remotely and interactively monitor through two-way communication and control an IP camera while using a personal communication device. Revolutionary Concepts has their headquarters in Charlotte, North Carolina and consultants located throughout the U.S. The Company's shares list on the OTC Markets: OTCQB.
More uses for the Eye Talk Communicator include medical applications, a sporting component, and infant care technology. Eye Talk offers intuitive and independent capabilities and sits upon a platform that interfaces effortlessly with smart devices including iPhone, iPad, Blackberry's, and Androids. Revolutionary Concepts holds patented and patent pending applications that use smart camera technology in medical/healthcare, sporting events, child monitoring and many other key areas.
Eye Talk incorporates a camera, built-in Web server, and network interface. It can manage areas of importance independently by providing programmable audio or by alerting designated users through an audio/video transmission to a smart phone or other compatible device. Features of Eye Talk include pre-recorded messaging capabilities; high-level security; convenient, flexible communication; instant identification; data collection and reporting; an archival system, and real time, two-way communication by way of computer, cell phone or PD.
Eye Talk technology offers administration portal management; motion activated connectivity, and remote control of PC-controller and camera. The technology also offers multi-level reporting capabilities and an expandable software platform.
Earlier this month, Revolutionary Concepts announced that the Company is actively pursuing the acquisition of a company generating significant revenues and net profits with the financial strength that could assist in the development of Revolutionary Concepts' technology and an execution of a commercialization strategy (sales and marketing).
Solomon RC Ali, Sr. VP, stated, "As we pursue this relationship, Management believes the acquisition could be valued at greater than $15 million. The company being evaluated has a current EBITDA in excess of $1 million."
Revolutionary Concepts, Inc. (REVO), closed today's trading session at $0.0019, up 11.76%, on 24,485,178 volume with 75 trades. The average volume for the last 60 days is 11,428,213 and the stock's 52-week low/high is $0.0006/$0.048.
The Wiki Group, Inc. (TWGI)
We are highlighting The Wiki Group, Inc. (TWGI) today, here at the QualityStocks Daily Newsletter.
Listed on the OTC Market's OTCQB, The Wiki Group, Inc. is an early-stage technology company whose dedication is to making financial transactions simple, secure, social and affordable. Wiki Group products include WikiPay, WikiBlast, and WikiLoan. Their proprietary online and mobile architecture is fully certified and compliant with industry-leading security standards. The Company's management team has decades of experience leading technology and telecommunications companies, ranging from high-tech start-ups to senior management roles at AT&T, IBM and Unisys. The Wiki Group has their corporate headquarters in Los Angeles, California. The Company was incorporated on June 24, 1988 as "Windsor Capital Corp."
The Company's WikiPay is a simple, low-cost alternative to existing mobile and online payment solutions. WikiPay allows users to send and receive money with any mobile device, over any carrier network. The Company's target market is primarily the un-banked and under-banked population around the world that uses check cashing and money transfer alternatives. WikiPay is a proprietary, fee-based mobile peer-to-peer payment and marketing platform that allows mobile and online peer-to-peer payments, B2C, C2B and B2B payments, and mobile marketing services via the Company's website www.wikipay.com and mobile website m.wikipay.com.
WikiBlast is a customizable mobile marketing engine. It has full integration with the WikiPay payment platform, which allows merchants to send product offers and messages to their customer base and generate sales. WikiBlast provides customizable mobile marketing messages that can reach clients instantly.
In addition, The Wiki Group offers WikiLoan, a low-cost peer-to-peer lending solution. Moreover, their WikiPay and WikiBlast work on any mobile phone, Smartphone or internet-enabled device. They take advantage of existing infrastructure to reduce changes in customer behavior, while reducing cost substantially.
The Wiki Group has developed key relationships and formed dedicated strategic partners to enable fast and effective customer adoption. The Company is negotiating distribution and marketing partnerships with companies including Prouty Co., TAC Financial, Fuzion Mobile, Telecomm Mexico, Agrobursa and Yankee USA.
The Wiki Group announced that the Company has signed a Letter of Intent (L.O.I.) to acquire MoneyTech. This is a platform along the lines of The Wiki Group's business. However, it is a B2B model instead of a consumer model.
The Wiki Group, Inc. (TWGI), closed Monday's trading session at $0.04, up 53.85%, on 875,900 volume with 103 trades. The average volume for the last 60 days is 230,841 and the stock's 52-week low/high is $0.0046/$0.205.
Titan Oil & Gas, Inc. (TNGS)
Dividend Opportunities, Wyatt Investment Research, Investor Ideas, Trade of the Week, SmallCapNetwork, and The Online Investor reported previously on Titan Oil & Gas, Inc. (TNGS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Founded in 2008, Titan Oil & Gas, Inc. is an exploration stage company that engages in the acquisition and exploration of oil and gas properties in Canada. The Company is primarily focusing on oil and gas exploration in the Province of Alberta. All of their projects are in areas of excellent infrastructure and highly active development. The Company formerly went by the name XtraSafe, Inc. They changed their name to Titan Oil & Gas, Inc. in June 2010. Titan Oil & Gas is based in Las Vegas, Nevada. The Company lists on the OTC Market's OTCQB.
Currently, Titan has five main oil and gas projects covering 6,959 acres of land near the cities of Lethbridge and Medicine Hat, Alberta. The Company owns 100 percent of the petroleum and natural gas rights for the full-depth in three of these projects. They own 100 percent of the petroleum and natural gas rights below the base of the Mannville in the remaining two.
The Company's projects include Atlee Buffalo, Bow Island, Eyremore, Retlaw, Taber, and CFB-Suffield. The Atlee Buffalo project is approximately 60 miles north of Medicine Hat in Alberta. Titan owns all the P&NG rights to this property, which contains one abandoned well, drilled in 1989. The Bow Island project is approximately twenty miles southwest of Medicine Hat.
The Eyremore project is approximately 48 miles north of Lethbridge, Alberta. There are eight producing gas wells on the lands; they produce from above the base of the Mannville formation. Titan owns all P&NG rights below the base of the Mannville formation. The Retlaw project is approximately 30 miles northeast of Lethbridge. It contains one abandoned well and one gas well producing from above the base of the Mannville. Titan owns all P&NG rights below the base of the Mannville formation.
The Taber project is approximately 30 miles east of Lethbridge. The CFB-Suffield region hosts several highly productive oil pools and is estimated to contain upwards of 1 billion barrels of oil in place. In addition, Titan Oil & Gas owns a 2.51255 percent Working Interest (WI) in an oil well located in Alberta. The Company has also acquired an interest in two P&NG leases in the province of Saskatchewan. The total area covered by their Saskatchewan leases is 326 acres.
Titan Oil & Gas, Inc. (TNGS), closed Monday at $0.013, even for the day, on 24,500 volume with 8 trades. The average volume for the last 60 days is 14,767 and the stock's 52-week low/high is $0.012/$0.15.
Torotel, Inc. (TTLO)
We are highlighting Torotel, Inc. (TTLO), here at the QualityStocks Daily Newsletter.
Based in Olathe, Kansas, Torotel, Inc. designs and manufactures a broad spectrum of magnetic components and electro-mechanical sub-assemblies. These products are for use in military, aerospace and industrial electronic applications. Torotel's products are used to modify and control electrical voltages and currents in electronic devices. The Company markets their products mainly through an internal sales force and independent manufacturers' representatives. Founded in 1956, Torotel lists on the OTCQB.
The Company conducts business primarily through their wholly owned subsidiary, Torotel Products, Inc. (Torotel Products). They also operate another wholly owned subsidiary Electronika, Inc. (Electronika). Another subsidiary, Torotel Manufacturing Corp. (TMC) provides manufacturing services to Torotel Products.
Torotel has worked with close to 1,000 companies domestically and globally. Torotel has a broad product portfolio with greater than 32,000 custom designs. Torotel Products has received recognition for their quality and performance by Raytheon Integrated Defense Systems. Torotel received a Supplier Excellence Award on April 13, 2011. Torotel provided Raytheon and their contractors with more than 15,000 custom magnetic components in 2010 - with a delivery and performance record that was among the best for Raytheon.
Torotel offers a number of parts to their clients. These include Transformers – single, 3-phase, current, RF, audio and switch mode; Inductors – tight tolerance signal processing, common mode, differential mode, filter, chokes and air coils, as well as Electromechanical assemblies. Also available from the Company are Commercial products for different applications such as down hole instrumentation, alarm systems and medical electronics. Their products are offered primarily in surface mount, through hole, and flexible lead wires, with alternate types of terminations available.
Torotel Products sells these products to original equipment manufacturers (OEMs). These OEMs use them in applications such as aircraft navigational equipment; digital control devices; airport runway lighting devices; medical equipment; avionics systems; down-hole drilling; and conventional missile guidance systems.
The industry mix of Torotel Products' net sales for the first six months of fiscal year 2013 was 68 percent defense, 7 percent industrial, and 25 percent aerospace. This is in comparison to 60 percent defense, 21 percent industrial and 19 percent aerospace for the same period in fiscal year 2012. In addition, approximately 98 percent of Torotel's sales during the first six months of fiscal year 2013 were garnered from domestic customers.
Torotel, Inc. (TTLO), closed Monday's trading session at $0.47, up 2.40%, on 48,570 volume with 11 trades. The average volume for the last 60 days is 3,512 and the stock's 52-week low/high is $0.11/$0.78.
Zevotek, Inc. (ZVTK)
OTCPicks and Stockpalooza reported previously on Zevotek, Inc. (ZVTK), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Founded in 2005, Zevotek, Inc. markets and sells innovative personal and home care items. The Company engages in the direct marketing and distribution of consumer products. They formerly went by the name Diet Coffee, Inc. They changed their corporate name to Zevotek, Inc. in June of 2008. Zevotek has their headquarters in Englewood Cliffs, New Jersey; the Company's shares trade on the OTC Bulletin Board.
On February 24, 2009, Zevotek entered into an Exclusive License and Sales Agreement giving them the worldwide rights to manufacture, market, use, and sell, distribute and advertise an air purifier contained in an energy saving compact fluorescent light bulb (the Ionic Bulb).
The Ionic Bulb is an air-purifying product. The air-purifying component of the Ionic Bulb is placed in the base of a compact fluorescent light "CFL" bulb. It consists of electronics and a spout through which negative ions produced by the air-purifying component undergo dispersion into the air.
The electricity used to operate the air-purifying component also lights the CFL bulb to illuminate a room in the same manner as ordinary CFL bulbs. The Company has currently stopped working on the sales of the Ionic Bulb. They are now working on upgrading the bulb. The new ionic bulb will be made with an LED light; it will no longer use fluorescent light.
On December 10, 2010, Zevotek entered into an Exclusive License and Sales Agreement giving the Company the worldwide rights to develop, manufacture, market, use, and sell, distribute and advertise a U.S. patented new product called "Gung H2O." This product reduces water use in the home. Gung H2O is a patented plumbing valve that is installed in the traditional gravity toilet tank of a non-low flow toilet.
The Gung H2O valve regulates the amount of water used to fill and flush a toilet. The valve is adjustable to enable the toilet to use more or less water as needed. The Gung H2O valve enables a traditional non-low flow toilet to use less water to achieve the equivalent level of flushing power of a non-low flow toilet.
After Zevotek tried to market the Gung H2O, the Company went back to the inventors to make changes due to feedback from the public. After the inventors make the desired changes, Zevotek hopes to market the product sometime in the second to third quarter of 2013. Zevotek's intention is to sell Gung H20 to major U.S. retail stores and directly to U.S. consumers using TV ads and Internet marketing.
Zevotek, Inc. (ZVTK), closed Monday's trading at $0.20, up 66.67%, on 15,563 volume with 4 trades. The average volume for the last 60 days is 312 and the stock's 52-week low/high is $0.06/$0.78.
Portlogic Systems, Inc. (PGSY)
Penny Stocks Profile, PennyTrader Publisher, HotOTC, Real Pennies, and SmallCapStockPlays reported earlier on Portlogic Systems, Inc. (PGSY), and we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Portlogic Systems, Inc. is a mobile and Internet software developer and kiosk solutions provider for electronic payments, marketing delivery, and community communication systems. Their objective is to continually research, develop, and market the most convenient and advanced software tools that receive information and manage daily tasks. Portlogic Systems is based in Toronto, Ontario. Incorporated in 2006, the Company's shares trade on the OTC Market: OTCQB.
Portlogic Systems originally established as a web 2.0 software developer and solutions provider. The Company has several dedicated server networks in both North America and Europe. From them, the Company presently offers an on-demand, hosted, B2B community management software solution.
Portlogic provides enterprise software solutions. These include m2Meet, a community networking software solution to socially network and connect using location based technology, such as GPS. Solutions additionally include m2Bank, a financial transactions system that facilitates bill payments, money transfers, and account management. Another solution that the Company offers is m2Market. This is a mobile marketing solution.
The Company also offers m2Ticket, a mobile ticketing sales engine that manages the sale and delivery of tickets through mobile phones for the transportation and entertainment industry. In addition, Portlogic offers m2Kiosk - a standard and custom kiosks hardware and software that integrates with mobile phone applications in the marketing, financial, and ticketing industries. Their growing suite of enterprise mobile phone software solutions allows industries such as banking, customer relationship management, ticketing, and marketing, the ability to manage transactions and information easily and efficiently.
Last week, Portlogic Systems announced the formation of a new subsidiary, which will go by the name VOIP 1, Inc. The VOIP 1 subsidiary is an FCC, 214 licensed, VoIP (Voice over Internet Protocol) based global telecommunications carrier providing a platform to deliver voice and data solutions to retail customers, business enterprises, and carriers around the world.
Portlogic Systems, Inc. (PGSY), closed Monday's session at at $0.075, up 42.86%, on 1,739,393,900 volume with 194 trades. The average volume for the last 60 days is 9,817 and the stock's 52-week low/high is $0.001/$0.495.
Advaxis, Inc. (ADXS)
The QualityStocks Daily Newsletter would like to spotlight Advaxis, Inc. (ADXS). Today, Advaxis, Inc. closed trading at $0.0357, off by 4.80%, on 8,475,179 volume with 200 trades. The stock’s average daily volume over the past 60 days is 1,476,532, and its 52-week low/high is $0.031/$0.179.
Advaxis, Inc. (ADXS) is a clinical-stage biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases. The company’s immunotherapies are based on a novel platform technology that uses live, bio-engineered bacteria to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to fight off cancer and disease.
The company has more than fifteen distinct constructs in various stages of development, all of which are involved in strategic collaborations with recognized centers of excellence such as the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.
Advaxis’ lead construct, ADXS-HPV, is currently in Phase 2 clinical development for recurrent/refractory and advanced cervical cancer, CIN 2/3, and HPV caused head and neck cancers. This important construct was recognized as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines.
The estimated global market for immunotherapies is projected to exceed $37.2B by 2012, with cancer vaccines forecast to grow into an $8B market. Protected by 77 issued and pending patents, Advaxis is extremely well positioned to capitalize on the burgeoning opportunities in the healthcare sector as it advances the development of next-generation treatments for today’s most challenging diseases. Disclaimer
Advaxis, Inc. Company Blog
Advaxis, Inc. News:
Advaxis Receives Preliminary Approval for Sale of Losses from State of NJ Economic Development Authority
Advaxis Presents at NYC MedTech Program
Advaxis Updates Phase 2 Cervical Cancer Trial Data
TNI BioTech, Inc. (TNIB)
The QualityStocks Daily Newsletter would like to spotlight TNI BioTech, Inc. (TNIB). Today, TNI BioTech, Inc. closed trading at $9.25, up 2.21%, on 15,384 volume with 44 trades. The stock’s average daily volume over the past 60 days is 43,961, and its 52-week low/high is $0.72/$10.01.
TNI BioTech, Inc. (TNIB) is focused on utilizing patented immunotherapy to activate and mobilize the body's immune system to combat fatal diseases. The company's products and technologies improve the treatment and diagnosis of cancer, infections such as HIV/AIDS, and autoimmune diseases. Future initiatives include treatment for multiple sclerosis, herpes viral infections, and other conditions that result in altered-immune response.
The company's product portfolio currently includes IRT-101, an active immunotherapy that works by activating a patient's immune system against infectious diseases and tumor cells; IRT-102, an adaptive immunotherapy that works by isolating and enriching a patient's own immune cells; and IRT-103, an active immunotherapy that works by activating a patient's immune system against HIV/AIDS and tumor cells.
Leveraging the advantages of today's cutting-edge treatment options, the company aims to meet the growing demand for quality healthcare with safer, more effective radiation therapy; new-targeted drug therapies; and minimally invasive surgical alternatives around the world. TNI BioTech most recently signed a letter of intent to open clinics in Africa that will provide advanced treatment for cancer, HIV/AIDS, and autoimmune diseases.
The company plans to continue clinical trials in China during 2012 and 2013, and anticipates starting trials in the United States by early 2013.The company is also in negotiations to acquire a number of other immunotherapy products, patents, and therapies. Led by a management team with decades of experience and solid business plan, TNI BioTech is poised to improve healthcare with active and adaptive forms of improved immunotherapies. Disclaimer
TNI BioTech, Inc. Company Blog
TNI BioTech, Inc. News:
TNI BioTech, Inc. Signs Exclusive Distributor Agreement for Federal Republic of Nigeria with G-Ex Technologies/St. Maris Pharma & GB Pharma Holdings LLC
TNI BioTech Inc., and Hubei Qianjiang Pharmaceuticals Co., Ltd., Announce Venture Partnership for the Development of New Drug for Cancer Therapies
Dr. Henry "Skip" Lenz, Pharm.D, Joins TNI BioTech, Inc., as Quality Control Officer
International Stem Cell Corp. (ISCO)
The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.206, up 0.49%, on 93,605 volume with 27 trades. The stock’s average daily volume over the past 60 days is 129,125, and its 52-week low/high is $0.161/$0.68.
International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
hpSCs are as pluripotent as embryonic stem cells (ESCs) and have significant therapeutic potential but their creation does not involve the destruction of a viable human embryo – thus sidestepping the controversy and ethical dilemmas associated with the use of human embryonic stem cells. Different from induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less differentiated stage – a practice that may become a safety or regulatory obstacle in clinical applications.
A relatively small number of hpSC lines can offer the potential of producing the first true stem cell bank, UniStemCell, which ISCO intends to create as a means of serving populations across the globe. The company's scientists are currently focused on using hpSC to treat severe diseases of the eye, nervous system, and liver, for which cell therapy has been clinically proven but is limited due to the unavailability of safe human cells.
In addition to its therapeutic focus, ISCO also provides two revenue streams. Firstly through its subsidiary Lifeline Cell Technology, specialized cells and growth media for biological research around the world, and secondly its subsidiary Lifeline Skin Care, the company manufactures and sells anti-aging skincare products utilizing an extract from the hpSC and by leveraging the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology. Disclaimer
International Stem Cell Corp. Company Blog
International Stem Cell Corp. News:
Lifeline Skin Care a Subsidiary of ISCO Announces New Sales and Multi-Media Marketing Campaigns
German Court Decision May Strengthen International Stem Cell Corporation's Position in European Market
International Stem Cell Corp to Participate in Fifth Annual LD Micro Conference
Consorteum Holdings, Inc. (CSRH)
The QualityStocks Daily Newsletter would like to spotlight Consorteum Holdings, Inc. (CSRH). Today, Consorteum Holdings, Inc. closed trading at $0.013, up 30.00%, on 648,950 volume with 9 trades. The stock’s average daily volume over the past 60 days is 178,903, and its 52-week low/high is $0.001/$0.018.
Consorteum Holdings, Inc. (CSRH) utilizes the most technically advanced global solutions available today. By working with a multitude of global technologies, Consorteum is able to create customized programs for maximum results. This approach enables unparalleled flexibility when sourcing solutions, resulting in smarter, faster deployment of technologies, competitive pricing, and potential for new streams of revenue.
Through its exclusive software license with Tarsin Inc., the company leverages a team of software developers that understands the complexities of delivering digital media content across mobile handsets. Tarsin is capable of providing clients with integration and support for over 700 mobile carriers globally on a seamless and secure platform to take advantage of the increasing demand for rich mobile content.
Consorteum's flagship CAPSA technology platform brings a universal solution to the problems of wagering and betting on mobile devices. Multiple different operating systems, user interfaces, and form factors have created enormous barriers to launching commercial initiatives. But with CAPSA, gaming operators can now cost-effectively monetize innovative mobile wagering products and services quickly and robustly.
In addition to its mobile initiatives, Consorteum is also actively engaged in the financial industry, providing MasterCard solutions as well as loyalty and reward programs. The company has strategically designed its business initiatives to create repetitive transactions on an ongoing basis. Consorteum's goal is to have their customers think of them more as partners, rather than just technology providers, for longer-lasting, more profitable relationships. Disclaimer
Consorteum Holdings, Inc. Company Blog
Consorteum Holdings, Inc. News:
Consorteum Holdings Files Form 10-K Report With the Securities and Exchange Commission
CORRECTION -- Tarsin, a Leader in Secure Mobile Platform Technology, Forges New Frontiers in Mobile Gaming
Tarsin, a Leader in Secure Mobile Platform Technology, Forges New Frontiers in Mobile Gaming
Integrated Electrical Services, an infrastructure services company with leading positions in a broad range of markets for electrical and communications products and services, announced financial results for its fiscal 2012 fourth quarter and year ended September 30, 2012.
James Lindstrom, Chairman and Chief Executive Officer, stated, “We are pleased with the performance improvement of IES in 2012. Our employees’ ownership mindset and their sharpened focus on delivering superior performance in our core fields of expertise has led to another quarter of revenue growth, margin improvement and increased backlog. We are poised to continue with and build upon the operational improvements that started in the fourth quarter of 2011. In fiscal 2013 our long term focus will remain on generating above average returns on a risk adjusted basis through disciplined capital deployment in our existing businesses or via acquisition.”
Key highlights for the fourth quarter include:
• Adjusted net income per share of $0.04 and adjusted EBITDA of $1.7 million, an improvement of $1.4 million year over year
• Net loss from continuing operations of ($0.4) million, or ($0.03) per share; adjusted net income of $0.6 million, or $0.04 per share, an improvement of $1.7 million year over year
• Revenue of $123.4 million, an increase of 11.5% year over year
• Gross profit of $16.8 million, an improvement of $2.9 million year over year
• Gross margins for the quarter improved to 13.6% of revenue as compared to a gross margin of 12.6% a year earlier
• Backlog was approximately $234 million at September 30, 2012, a $5 million increase from June 30, 2012
Key year end financials include:
• Net loss from continuing operations of ($2.7) million, or ($0.18) per share; adjusted net income of $0.9 million, or $0.06 per share, an improvement of $16.3 million year over year
• Revenue of $456.1 million, an increase of 12.3% year over year
• Gross profit of $58.1 million, an improvement of $13.7 million year over year
• Gross margins for the fiscal year improved to 12.7% of revenue as compared to a gross margin of 10.9% a year earlier
• Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization and other items) of $5.2 million, an improvement of $14.8 million year over year
Integrated Electrical Services is an infrastructure services company with leading positions in a broad range of markets for electrical and communications products and services. The company has 2,500 employees who serve clients throughout the United States. For further details on the company’s financial results, please refer to the annual report on Form 10-K for the fiscal year ended September 30, 2012.
For more information, please visit www.ies-corporate.com
InVivo Therapeutics, a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, announced that it has pursued a Humanitarian Use Device (HUD) designation for its biopolymer scaffolding product by filing a request with the U.S. Food and Drug Administration (FDA). The company is currently in works with the FDA to finalize the approval process and begin clinical trial of the scaffolding acute SCI in early 2013.
Humanitarian Use Devices, commonly referred to as HUDs, are developed to treat rare diseases or conditions. InVivo seeks to obtain this designation for its biopolymer scaffolding for use in the treatment of complete function spinal cord injuries that do not involve penetrating injury or the complete severing of the spinal cord.
InVivo met with the FDA in April 2012 to discuss the requirements for obtaining HUD designation and the potential for the device to be regulated and distributed under a Humanitarian Device Exemption (HDE). Obtaining both a HUD and HDE designation would enable the company to commercialize the devices in the United States faster than the Pre-Market (PMA) approval process.
“The HUD/HDE provision provides a pathway for obtaining market approval from FDA for medical devices that may help people with rare diseases or conditions that otherwise would be remain unmet,” said InVivo Director of Regulatory Affairs Jack Bonasera. “InVivo is confident that the results of well designed pre-clinical studies will satisfy the primary HDE requirements in this type of devastating injury where no motor or sensory function is present below the level of neurological injury.”
“HUD designation is not only important for speed-to-market but also represents a benchmark in InVivo’s commitment to patients with spinal cord injuries and other neurotrauma conditions. Our GMP team is ready to go, and our clean room is humming. We expect 2013 to be a breakout year for InVivo stakeholders as we advance additional products into the FDA process,” stated Frank Reynolds, InVivo Chief Executive Officer.
InVivo has stated that it expects to receive further feedback from the FDA on the HUD request in January 2013.
For more information on InVivo, visit www.invivotherapeutics.com
Bullfrog Gold, the domestic mineral developer with a deep management bench of seasoned industry veterans and a firm gold project acreage footprint in Arizona and Nevada, reported good news out of their Newsboy Project today, which has expanded to 4,958 acres (including state lands) with the leasing of two new patented mining claims in the Queen of Sheba (QoS) area, 2.5 miles northwest of the main deposit.
The new leases are a beautiful little patch of geology covering some 38 acres containing numerous mineralized outcrops and adits, having similar geophysical characteristics overall with the main Newsboy deposit. Shallow shafts and prospect pits exist in the QoS target area, but there is no historical record of production on-site from former owner Moneta Porcupine Mines, whose last work on the site was in late 1994.
The last data points we have are from the outcrop chip and channel sampling done by Moneta which showed a 260-foot strike length on the surface, with 0.064 opt over 54 feet on average, in addition to the 1995 core hole (intercepts ranging from 0.024 opt Au and 0.14 opt Ag over 16 feet to 0.124 opt Au and 0.31 opt Ag over 2 feet). So we have clear indications from the component data sets that the surface sampling is the hallmark of a deeper 492-foot wide geophysical anomaly which was traced over a strike (open on both ends) length of some 1.64k feet.
Considering the recent expansion of the thick, high-grade mineralization area as a result of Phase II drilling on the main deposit at Newsboy reported back in late August (pit limit expanded by an 800 by 1.2k-foot area via a 24-hole program, high-grade gold upwardly revised 20% from the previous 0.044 opt Au figure), these leases make a great deal of sense and Bullfrog will test for expansions to that newly found yellowy goodness in the upcoming program slated for the QoS target area. Bullfrog plans to put in some 24 holes over the next few months to test the excellent intercepts from extant Moneta data, as well as for that possible extension to the newly discovered thick slice of mineralization at the main deposit, with resource estimates and a preliminary mine plan shortly thereafter.
Newsboy is just 45 miles outside Phoenix (excellent logistics) and sits just 10 miles east of one of the states highest-grade, largest gold mines, the Vulture Mine. Historic resource estimates are 235k oz Au with 3.4M oz Ag (5.4M tons at 0.044 opt and 0.64 opt respectively) and the last production data point is from 1942, where 11k tons of ore grading on average 0.07 opt Au, with 8 opt Ag were shipped to a local smelter.
Reported terms of the lease call for a one-time $100k work commitment for the next year on the QoS target area, a $10k annual payment, and royalties in the 1% to 5% range based on gold being in the $1.2k to $5k price range. A solid move that is in the interests of BFGC shareholders and one that reinforces the company’s overall regional position.
For more information, visit www.BullFrogGold.com
Advanced Cell Technology Inc. today announced the completion of the second patient cohort of the company’s European clinical trial for Stargardt’s Macular Dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).
The conclusive fifth and sixth patients were injected with 100,000 hESC-derived RPE cells, as compared to 50,000 cells in the first cohort; the company reports that both patients are recovering uneventfully.
“Having completed the second, higher-dose patient cohort in all three of our clinical trials in the U.S. and Europe, we are now officially at the halfway point in all three, which we find very gratifying,” Gary Rabin, chairman and CEO of Advanced Cell stated in the press release. “We have been able to add new trials sites and consequently to quicken the pace of patient enrollment in our ongoing trials. We feel this should also serve to hasten the pace at which we are able to complete the second half of the trials.”
The European clinical trial is one of the three trials being carried out by the company in the U.S. and Europe, and represents an important achievement in the company’s progress.
“Completing the higher-cell dosage in all three of our trials is a significant milestone in our RPE program,” said Robert Lanza, M.D., Advanced Cell chief scientific officer. “At our current pace of patient treatments, we should be on track to complete all three trials in 2013.”
Each of the three trials will enroll a total of 12 patients, with cohorts of three patients in an ascending dosage format. These trials are prospective, open-label studies designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation into patients with dry AMD or SMD at 12 months, the study’s primary endpoint.
For more information, visit www.advancedcell.com
Today's Top 3
The QualityStocks Public Company Sponsor News